Literature DB >> 7511336

Heterologous expression of delta F508 CFTR results in decreased sialylation of membrane glycoconjugates.

A Dosanjh1, W Lencer, D Brown, D A Ausiello, J L Stow.   

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is commonly mutated in cystic fibrosis to the delta F508 CFTR. CFTR has been shown to function as a adenosine 3',5'-cyclic monophosphate-dependent Cl- channel at the cell surface, and there is evidence to suggest that CFTR may also have a role in transmembrane Cl- conductance in intracellular membrane compartments. Studies using cells from cystic fibrosis patients or heterologous expression systems have demonstrated that defective Cl- conductance at the cell surface and defective acidification of the Golgi compartment are associated with the presence of mutant forms of CFTR. It is possible that mutation of CFTR could also result in altered Golgi function, consistent with reports of changes in the glycosylation of cell surface and secreted glycoproteins in cystic fibrosis. Glycosylation of cell surface glycoproteins, particularly levels of sialylation, may also be related to the increased binding of Pseudomonas to cystic fibrosis cells. The current study was undertaken to compare the sialylation of cell surface glycoconjugates in heterologous cells overexpressing normal CFTR or delta F508 CFTR. The presence of sialylated residues on cells was assessed by the surface binding of the specific lectins, wheat germ agglutinin and elderberry bark lectin. A fluorescent cholera toxin B subunit probe was used to measure surface binding to sialylated gangliosides in transfected cells. Our studies show that cells lacking CFTR and cells expressing normal CFTR have unaltered levels of sialylation. In contrast, cells expressing the delta F508 CFTR have significantly decreased amounts of sialylated glycoproteins and gangliosides on the cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511336     DOI: 10.1152/ajpcell.1994.266.2.C360

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

Review 1.  New therapeutic approaches for cystic fibrosis lung disease.

Authors:  Jane C Davies
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung.

Authors:  J F Poschet; J C Boucher; L Tatterson; J Skidmore; R W Van Dyke; V Deretic
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased β1-integrin signaling and delayed wound repair.

Authors:  Yutaka Itokazu; Richard E Pagano; Andreas S Schroeder; Scott M O'Grady; Andrew H Limper; David L Marks
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-05       Impact factor: 4.249

Review 4.  Human airway mucin glycosylation: a combinatory of carbohydrate determinants which vary in cystic fibrosis.

Authors:  G Lamblin; S Degroote; J M Perini; P Delmotte; A Scharfman; M Davril; J M Lo-Guidice; N Houdret; V Dumur; A Klein; P Rousse
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

5.  Biosynthesis of mucin type O-glycans: lack of correlation between glycosyltransferase and sulfotransferase activities and CFTR expression.

Authors:  I Brockhausen; F Vavasseur; X Yang
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

Review 6.  Terminal glycosylation in cystic fibrosis (CF): a review emphasizing the airway epithelial cell.

Authors:  A D Rhim; L Stoykova; M C Glick; T F Scanlin
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

7.  Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis.

Authors:  Ema Robinson; Kelvin D MacDonald; Kai Slaughter; Madison McKinney; Siddharth Patel; Conroy Sun; Gaurav Sahay
Journal:  Mol Ther       Date:  2018-06-15       Impact factor: 11.454

8.  A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.

Authors:  P J French; J H van Doorninck; R H Peters; E Verbeek; N A Ameen; C R Marino; H R de Jonge; J Bijman; B J Scholte
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

Review 9.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

10.  Expression of DeltaF508 Cystic Fibrosis Transmembrane Regulator (CFTR) Decreases Membrane Sialylation.

Authors:  Amrita Dosanjh; Elaine A Muchmore
Journal:  Open Respir Med J       Date:  2009-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.